13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001053906
Total reported value
$931.1M
$931.1M
109 檔
297.2%
According to the latest 13F quarterly dataset, Artal Group S.A. managed an equity portfolio of $931.1M at the end of Q2 2024, spanning 109 distinct U.S. exchange-listed positions.
During Q2 2024, Artal Group S.A.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CAVA | Cava Group Inc | Stock-Consumer Disc | 55.59% | -21.26% | -11.32% | |
| 2 | LXRX | Lexicon Pharmaceuticals Inc | Stock-Other | 7.50% | +21.26% | +48.95% | |
| 3 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 2.78% | — | +15.20% | |
| 4 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.39% | — | — | |
| 5 | KYMR | Kymera Therapeutics Inc | Stock-Other | 2.29% | — | -0.71% | |
| 6 | MORFUSD | Morphic Holding Inc | Stock-Other | 2.19% | — | +14.13% | |
| 7 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.43% | — | +11.54% | |
| 8 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.36% | — | -0.07% | |
| 9 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.35% | — | — | |
| 10 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.26% | — | -7.23% | |
| 11 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.22% | — | -23.33% | |
| 12 | ✓ | Merus N V | Stock-Other | 1.15% | — | +67.08% | |
| 13 | ONC | Beone Medicines Ltd-adr | Stock-Other | 1.10% | — | -25.05% | |
| 14 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 1.01% | — | -22.97% | |
| 15 | KURA | Kura Oncology Inc | Stock-Other | 0.96% | — | -5.21% | |
| 16 | VERA | Vera Therapeutics Inc | Stock-Other | 0.84% | — | +81.02% | |
| 17 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.71% | — | -3.42% | |
| 18 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.68% | — | -2.40% | |
| 19 | RNAGBP | Avidity Biosciences Inc | Stock-Other | 0.68% | — | — | |
| 20 | 1K0 | Igm Biosciences Inc | Stock-Other | 0.58% | — | +8.12% | |
| 21 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.58% | — | +12.71% | |
| 22 | ERAS | Erasca Inc | Stock-Other | 0.58% | — | +103.99% | |
| 23 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.55% | — | +14.81% | |
| 24 | PRTA | Prothena Corporation plc | Stock-Other | 0.53% | — | — | |
| 25 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.49% | — | +49.56% | |
| 26 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 0.47% | — | — | |
| 27 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.39% | — | — | |
| 28 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.38% | — | +50.58% | |
| 29 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.37% | — | — | |
| 30 | SLDB | Solid Biosciences Inc | Stock-Other | 0.36% | — | — | |
| 31 | KRRO | Korro Bio Inc | Stock-Other | 0.36% | — | -1.47% | |
| 32 | ASND | Ascendis Pharma A/S | Stock-Other | 0.35% | — | — | |
| 33 | AGEN | Agenus Inc | Stock-Other | 0.33% | — | — | |
| 34 | SYRS | Syros Pharmaceuticals Inc | Stock-Other | 0.33% | — | — | |
| 35 | GOSS | Gossamer Bio Inc | Stock-Other | 0.31% | — | — | |
| 36 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 37 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.29% | — | +54.55% | |
| 38 | BHVN | Biohaven Ltd. | Stock-Other | 0.27% | — | — | |
| 39 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.25% | — | +18.08% | |
| 40 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.25% | — | -24.73% | |
| 41 | ✓ | Acelyrin Inc | Stock-Other | 0.23% | — | -15.98% | |
| 42 | JANX | Janux Therapeutics Inc | Stock-Other | 0.22% | — | +306.00% | |
| 43 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 44 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.21% | — | — | |
| 45 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 0.21% | — | — | |
| 46 | GBIOGBX | Generation Bio Co | Stock-Other | 0.20% | — | — | |
| 47 | SEER | Seer Inc | Stock-Other | 0.20% | — | — | |
| 48 | VIGL | Vigil Neuroscience Inc | Stock-Other | 0.19% | — | +0.97% | |
| 49 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 0.19% | — | — | |
| 50 | SE | Sea Ltd-adr | Stock-Comm Services | 0.18% | — | -58.95% |
According to official SEC Form 13F filings, Artal Group S.A. reported a total U.S. public equity portfolio value of $931.1M across 109 disclosed positions in Q2 2024.
During Q2 2024, Artal Group S.A.'s top holdings by market value included CAVA (55.6%)、LXRX (7.5%)、ARWR (2.8%). The largest single position, CAVA, represented 55.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CAVA, LXRX, ARWR) accounted for 297.2% of total reported equity market value during Q2 2024.
In Q2 2024, Artal Group S.A. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.